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Cross-platform multiplex detectiona b s t r a c t
Chromatin contains valuable epigenetic information comprising of bothDNAandpost translational histone
modiﬁcations. Traditionally, detection of epigenetic modiﬁcations on DNA and histone proteins requires
different and elaborate preparation steps. In this study we report on a facile and unique approach for the
simultaneous detection and quantiﬁcation of epigenetic modiﬁcations on DNA and histone proteins in
one sample preparation step. Our novel one-pot technique consists of a chromatin extraction step from
whole blood using bi-functional carboxyl-functionalized magnetic nanoparticles as solid-phase absor-
bents. Leucocytes enrichment from blood and chromatin extracted from the leucocytes by lysis was
achieved with the same carboxyl-functionalized magnetic nanoparticles. The isolated chromatin was then
eluted from the magnetic nanoparticles with PBS 1. Using the eluted chromatin as substrate, we
developed a quantitative method for simultaneous detection of epigenetic modiﬁcations on DNA and
histone proteins by a biotin–streptavidin mediated enzyme-based immunosorbent assay (two-step EIA)
on a 96-well plate. The simultaneous detection of epigenetic modiﬁcations on DNA and histone was vali-
dated by DNA-based EIA and histone-based Western blotting analysis performed separately with conven-
tional protocols. By coupling cell separation and chromatinpuriﬁcationwith a simple detectionmodule, the
global epigenetic information could be evaluated in less than 8 h in leucocytes from blood. Our simpliﬁed
cross-platform approach can be used by most laboratories for multiplex detection, uses non-hazardous
materials and could be integrated with microfabrication methods for onchip analysis.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epigenetic regulation is essential for normal development and
maintenance of tissue-speciﬁc gene expression patterns in mam-
mals [1]. There are two levels of epigenetic regulation in cells:
one constitutes the DNA modiﬁcations containing methylation
and hydroxymethylation on the 5th carbon of cytosine (5mC and
5hmC, respectively) among others, another is the posttranslational
histone modiﬁcations including methylation, acetylation,
phosphorylation, ADP-ribosylation and ubiquitination [2]. Global
epigenetic modiﬁcations in some cases have been considered as
the hallmark of leukemogenesis [2–5] and in general can be used
to assess the state of health of cells in blood. A simple test to detect
and quantify epigenetic biomarkers on DNA and histones simulta-
neously in chromatin extracted from cells in whole blood can be
valuable for routine screening and prognostics.Leucocytes which are less than 1% of the hemocytes present in
blood and are the only cell type containing chromatin in blood [6].
In patients with leukemia, these cells are immature and are subject
to malfunction. Enrichment of leucocytes from whole blood is a
required ﬁrst step of diagnosis. The conventional density gradient
centrifugation method for enriching leucocytes is labor and time
consuming (30 min) [7] and the commercialized kits using
anti-human leukocyte coated particles are not robust (due to fragi-
lity of bioactivity of the antibodies) and expensive for routine
analysis ($18 per reaction). Conventional chromatin-preparation
methods involving precipitation and centrifugation cannot adapt
to the micro total analysis systems (‘‘lTAS’’ or called
‘‘lab-on-a-chip’’) [6,8–13]. We reported a chromatin extraction
method from cultured mammalian cells using salicylic acid coated
magnetic nanoparticles [14]. However, this approach still required
enrichment of cells with centrifugation, not ideal for lab-on-a-chip
analysis. Here, we developed a rapid and reliable protocol to
extract and prepare chromatin from whole blood using
carboxyl-functionalized magnetic nanoparticles. The magnetic
40 Z. Zhou et al. / Analytical Chemistry Research 4 (2015) 39–44nanoparticles used as solid adsorbents could enrich leucocytes and
further nonspeciﬁcally adsorb chromatin released from the
enriched cells. The magnetic separation protocol demonstrated in
this effort based on the one-pot method could be easily used for
constructing a lab-on-a-chip system for routine screening of
patients and prognosis based on epigenetic analysis [6].
Based on the novel chromatin extraction method from cells in
blood, we further developed a biotin–streptavidin mediated
enzyme-based immunosorbent assay (two-step EIA) to simultane-
ously detect epigenetic marks on DNA and histone proteins in a
96-well plate format using our enhanced immunoassay platform.
Compared to conventional methods, which requires separate sam-
ple preparation steps to detect DNA modiﬁcations or histone mod-
iﬁcations, our approach is fast, cheap and robust. By coupling cell
separation, chromatin puriﬁcation and epigenetic mark quantiﬁca-
tion, we demonstrate a facile approach where the whole operation
can be accomplished within 8 h, which otherwise would take
2–3 days.
2. Experimental
2.1. Materials and chemicals
Carboxyl-functionalized magnetic nanoparticles (10 mg/ml)
were synthesized according to previous reports [15]. Clinical blood
samples were collected from 9 healthy donors (4 males and 5
females) and stored in 80 C until further use. All studies were
approved by Institutional Review Boards (IRB) protocols at their
respective institutions. Informed consent forms were obtained
from all subjects. Non-neoplastic S1 HMT-3522 human mammary
epithelial cells (S1 cells) were cultured according to standard pro-
tocols. The S1 cells were treated with conjugated linoleic acid (CLA)
and ethanol (as a control) to inﬂuence the histone modiﬁcation
proﬁle.
DNA coating solution, succinimidyl-6-[biotinamido]-6-hexanami
dohexanoate (NHS-LC-LC biotin), succinimidyl 4-(N-maleimidomet
hyl)cyclohexane-1-carboxy-(6-amidocaproate) (LC-SMCC), succin-
imidyl 6-[3(2-pyridyldithio)propionamido] hexanoate (LC-SPDP),
dithiothreitol (DTT), horseradish peroxidase (HRP), Sephadex G-15,
Mouse anti-rabbit IgG antibody were purchased from Pierce
(Rockford, IL). Casein, Tween 20, tetramethylbenzidine (TMB),
sodium dodecyl sulfate (SDS), phenylmethylsulfonyl ﬂuoride
(PMSF), ethylenediaminetetraacetic acid disodium salt (EDTA) and
glutaraldehyde were obtained from Sigma (St. Louis, MO). Rabbit
anti-5hmC antibody was supplied by Active Motif (Carlsbad, CA).
Streptavidin was purchased from Prozyme (Hayward, CA). 2%
Protease Inhibitor cocktailwas purchased fromNewEngland Biolabs.Figure 1. Transmission electron microscopy (TEM) images. Leucocytes captured by ca
visible on the surface of cells (indicated by white arrow).2.2. Chromatin extraction from frozen blood
Chromatin was puriﬁed from frozen blood as follows. Typically,
0.3–1 ml of thawed blood sample was placed in 1.5 ml sterilized
eppendorf tubes containing 10 ll carboxyl-functionalized mag-
netic nanoparticles (10 mg/ml). After gentle mixing, the blood
samples and magnetic nanoparticles were incubated in room tem-
perature for 10 min to allow the formation of leucocyte-magnetic
nanoparticle complexes. These complexes are collected by
magnetic separation (SuperMag Multitube Separator™, Ocean
NanoTech, San Diego), and the red supernatant was discarded
and the immobilized leucocytes were rinsed with PBS 1  3 times.
The complexes were then lysed by the addition of 50–80 ll of lysis
buffer (250 mM SDS, 1 mM EDTA, 0.5 mM EGTA, 1 mM PMSF and
2% Protease Inhibitor cocktail), by pipetting up and down slowly
20 times to denature and rupture the cell/nuclear membrane and
incubated for another 10 min. Cooled isopropanol (the same
amount as the lysis buffer) was added to the lysates and incubated
for 5 min. The chromatin-magnetic nanoparticle complexes were
collected again via magnetic separation; the supernatant was dis-
carded and the complex was rinsed once with 200 ll of cooled
70% ethanol. After the removal and evaporation of ethanol,
chromatin was eluted in 50 ll of PBS 1 at room temperature for
at least 1 h. A further magnetic separation step was performed to
collect the released chromatin in the supernatant. The concentra-
tion of puriﬁed chromatin was determined at OD260 and stored at
20 C until further use.
2.3. Two-step enzyme-linked immunosorbent assay
200 ng of puriﬁed chromatin was added to a polystyrene
microwell plate followed by mixing with 50 ll DNA coating solu-
tion and 50 ll glutaraldehyde (1%) at room temperature for 2 h
with gentle agitation. After washing with distilled water (DIW)
three times, the residual surface was blocked with 0.5% (w/v)
casein in PBS at 37 C for 1 h. Subsequent incubation with the pri-
mary antibody (0.5 lg/ml, 100 ll), diluted in PBS 1 containing
0.5% casein and 0.1% Tween 20 was performed for 1 h at 37 C to
target relevant epigenetic modiﬁcations (5mC, 5hmC, H4 and
H3K9me2). After washing, biotinylated secondary antibodies
speciﬁc to each primary antibody (0.5 lg/ml, 100 ll) was added
and incubated for 1 h at 37 C. Finally, streptavidin conjugated to
HRP (0.25 lg/ml, 100 ll) was added and incubated for 1 h at
37 C. For signal generation, 200 ll of the colorimetric substrate
mixture (1000:10:1 volume ratio of the following: 50 mM sodium
acetate buffer, pH 5.1; 1% (w/v) tetramethylbenzidine; 3% (v/v)
H2O2) was added to the microwell plate and kept at roomrboxyl-functionalized magnetic nanoparticles. A few clusters of nanoparticles are
Figure 2. Chromatin extraction efﬁciency. (A) Chromatin extracted from 400 ll of blood with 4–20 ll of MNPs. (B) Chromatin extracted from 300 to 900 ll of blood with
10 ll of MNPs. All of the chromatin was eluted into 50 ll of PBS 1.
Figure 3. TEM images of extracted chromatin in cells from blood – negatively stained with 2% uranyl acetate. Both images show that chromatin is organized into
heterochromatin and euchromatin. The heterochromatin is indicated by black arrow. Compared to euchromatin, heterochromatin is much harder to be accessed by
transcription factors as well as antibodies.
Figure 4. Comparison between the two-step EIA and the conventional one-step EIA
to detect histone H4 as a test case. The required chromatin for the two-step EIA was
10 ng while the one-step EIA required 100 ng.
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sulfuric acid to halt the reaction. The optical intensity was ﬁnally
measured at 450 nm with the VersamaxTM absorbance microplate
reader (Molecular Device; Sunnyvale, CA). Conventional EIA was
performed under the same conditions by using secondary antibod-
ies labeled with HRP instead of using biotinylated secondary anti-
body and streptavidin-HRP conjugate. A two-step EIA using DNA as
substrate instead of chromatin was also performed for validation
to assess whether chromatin extracted by our method could be
used as a substrate to detect epigenetic modiﬁcations on DNA [16].
2.4. Western blotting analysis
The extracted chromatin was mixed with a 6 loading buffer
(0.375 M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6 M DTT, 0.06% bro-
mophenol blue) and incubated at 37 C for 20 min, then separated
by electrophoresis through SDS–PAGE gels (crosslinking indicated
in ﬁgure legends) and transferred on to polyvinylidene ﬂuoride
membranes. The membrane was blocked with 5% milk to minimize
non-speciﬁc antibody binding and then probed with speciﬁc pri-
mary antibodies. All antibodies were diluted in the blocking buffer
and incubated overnight at 4 C in a wet chamber. The correspond-
ing HRP-conjugated secondary antibodies were incubated with
membranes at room temperature for 45 min. Protein bands were
Figure 5. Chromatin as substrate for 5mC and 5hmC quantiﬁcation compared with DNA as substrate. Quantiﬁcation of 5mC and 5hmC by two-step EIA uses DNA or
chromatin as substrate (A), and the corresponding 5mC/5hmC ratio in DNA and chromatin is determined (B). The detection of DNA modiﬁcations using chromatin as a
substrate is similar to using DNA as a substrate.
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Lightning Plus-Enhanced Chemiluminescence Substrate (Perkin
Elmer Life & Analytical Science). Images were further quantiﬁed
by ImageJ software.3. Results and discussion
3.1. Isolation of chromatin using bifunctionlized magnetic
nanoparticles
Functionalized super paramagnetic nanoparticles, where mag-
netization exists only when an external magnetic ﬁeld is applied
have been extensively used in bio-separation studies [17–20]. For
example, in the proposed chromatin immunoprecipitation assay,
magnetic nanoparticles was used to capture DNA fragments that
wrap histone proteins (associated with speciﬁc histone posttrans-
lational modiﬁcations) when they are functionalized with the cor-
responding histone antibodies. These particles can also be used for
cell collection and DNA preparation through nonspeciﬁc binding
[21,22]. Here, we ﬁrst used bi-functional magnetic nanoparticles
(MNPs) to simplify the process of chromatin extraction from leuco-
cytes in whole blood to realize the development of lab-on-chip
devices where chromatin can be used as substrate.
The carboxyl-functionalized MNPs bind to the leucocytes’ cell
membrane without speciﬁc interaction (shown in Fig. 1) and the
leucocytes were nonspeciﬁcally isolated fromwhole blood by mag-
netic separation. The MNPs randomly deposit on the cell surfaces
rather than targeting speciﬁc cell surface markers, indicating the
non-speciﬁc nature of their interaction [23]. Some reports also
show that carboxyl-functionalized MNPs can nonspeciﬁcally
enrich cells from different sources such as blood, saliva, urine
and bacterial culture [15,23–25]. Contaminants such as erythro-
cytes, carbohydrates, lipids and proteins, were left in the super-
natant and removed. Further, washing with PBS 1 was
accomplished to remove contaminants to a large extent. Thus,
the MNPs demonstrate their ability to enrich leucocytes from
whole blood via an easy, fast and reliable process.
Besides the enrichment of leucocytes, the carboxyl-
functionalized MNPs can also be used to isolate the corresponding
chromatin released from these cells and hence play a dual role.
During chromatin extraction, it is not necessary to remove the
nanoparticle-cell complexes since these can be directly lysed in
the same tube. After cell lysis with isopropyl alcohol (treated for
5 min), the released chromatin was adsorbed onto theMNP surface.
This step will induce chromatin molecules to transition from an
elongated coil conformation to a compacted spherical form. The
polycations in solution would mediate the electrostatic interactionbetween carboxyl coatedMNPs and the available phosphate groups
on DNA, resulting in chromatin attachment onto the MNP surface
[14,26]. The attached chromatin could then be eluted from the
nanoparticles with PBS 1 (50 ll). Thus, the enrichment of leuco-
cytes and the adsorption of chromatin can be integrated and the
whole extraction can be completed in a single tube.
To determine the chromatin extraction efﬁciency and to opti-
mize the experimental conditions, different aliquots of MNP sus-
pension were added to a ﬁxed volume (400 ll) of frozen blood.
Each extraction was repeated three times. Fig. 2A shows that chro-
matin concentration reached a peak when the nanoparticle con-
centration reached 10 ll of MNPs (100 lg in quantity). This
indicates that the enrichment efﬁciency of leucocytes and elution
efﬁciency of chromatin by MNPs, will determine the chromatin
extraction efﬁciency. Before reaching the peak, the more leuco-
cytes captured the higher is the yield of the chromatin extraction;
while after the optimal point, the absorbed chromatin cannot be
washed into the elution buffer when excess MNPs are added. By
increasing the volume of the blood samples (from 0.3 to 0.9 ml)
with the same amount of MNPs (10 ll), increased concentration
of chromatin (Fig. 2B) can be obtained. Though the extraction of
leucocytes in different patient samples varied using our approach,
at least 5 lg of chromatin could be extracted from 1 ml of whole
blood sample.
Fig. 3 shows the chromatin under TEM via negative staining (2%
uranyl acetate, UA). From the image, it can be seen that long and
thin chromatin ﬁbers covered the entire carbon coated copper grid.
Their length is much longer than the diameter of the nucleus
(1012 lm), indicating that besides nucleosome and higher order
chromatin structure, nuclear matrix would also assist in the com-
paction of the chromatin ﬁbers inside the nucleus. We also noted
that some part of the chromatin ﬁbers (indicated with black
arrows) are more heavily stained and compacted than other ﬁbers.
These could constitute the heterochromatin, which are hard to
access by transcription factors and is highly associated with the
down regulation of certain genes residing in these locations.
Others might be euchromatin, which are loosely compacted and
can be easily accessed by transcription factors and highly associ-
ated with gene expression.3.2. Determination of epigenetic modiﬁcations via a two-step EIA
DNA and histone modiﬁcations are the two key epigenetic
marks that play critical role in gene expression. The stepwise cre-
ation of distinct epigenetic patterns throughout the genome drives
the formation of different cell lineages during development. These
unique patterns dictate gene expression proﬁles, demarcate
Figure 6. Quantiﬁcation of the H3K9me2/H4 ratio by the two-step EIA (A) compared to Western blotting analysis (B). The two analytical methods give similar result
indicating that the global level of H3K9me2 drops after treating the S1 cells with CLA.
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tion and cell division to maintain distinct cell lineages [27,28].
Leukemia is a heterogeneous disease with widespread aberration
of epigenetic marks [2,29]. These epigenetic alterations can be used
as biomarkers for cancer detection, diagnosis and prognosis [30].
Most of the efforts have predominantly either studied DNA
[31,32] or histone modiﬁcation independently [33–36] or focused
on elucidating the epigenetic patterns of speciﬁc genes [37,38]
because one requires DNA and the other requires histone proteins.
For the ﬁrst time, we attempt to evaluate both DNA and histone
modiﬁcations simultaneously in a single platform.
To achieve increased signal ampliﬁcation, we used a two-step
(primary antibody, secondary antibody-biotin and streptavidin-
HRP) enzyme-linked immunosorbent assay (two-step EIA) to detect
epigenetic modiﬁcations on DNA and histone proteins using the
same sample. We compared our method with the conventional
one-step (primary antibody, secondary antibody-HRP) EIA (using
histone H4 as a test case), and found that the two-step EIA required
10 ng of chromatin, while the one-step EIA required 100 ng of chro-
matin (as shown in Fig. 4). Further, since streptavidin can be labeled
with multiple HRP molecules, upon interaction with biotin-labeled
antibody an enhanced signal proportional to the number of HRP
molecules can be expected from this reaction [16] (Fig. 5).
In order to verify whether the extracted chromatin from blood
could be used to determine DNA modiﬁcations, we compared our
method with the conventional DNA-based EIA. DNA methylation
(5mC) is one of the characteristic hallmarks of mammalian hete-
rochromatin where 5mC marks on DNA are hidden inside the
highly compacted chromatin ﬁber, as shown in Fig. 3. DNA hydrox-
ymethylation (5hmC) is mostly associated with euchromatin,
which is much more accessible and easier to be detected than
5mC in chromatin. In the extracted DNA by conventional
approaches, a compact form does not exist, and 5mC and 5hmC
have equal opportunity for assess. Thus, the 5mC/5hmC ratio
should be higher in DNA than that in chromatin due to the lack
of access by 5mC targeting antibodies in the heterochromatin.
Our result shows that the 5mC/5hmC ratio is 1.26 in DNA and
1.21 in chromatin, which is consistent with our hypothesis. The
detection of DNA modiﬁcations using chromatin as a substrate is
similar to using DNA as a substrate. Thus, samples used in our
method are suitable for the detection of epigenetic modiﬁcations
in DNA.
In order to verify whether chromatin could be used to deter-
mine histone modiﬁcations, we compared our two-step EIA with
Western Blotting analysis (WB). We used the conjugated linoleic
acid (CLA) treated S1 cells as a model to assess its effect on histone
H3 lysine 9 di-methylation (H3K9me2). Ethanol (EtOH) was used
as a control. Chromatin was extracted by the developed approachfrom S1 cells and one half of it was used for WB analysis; the other
half was used for the two-step EIA analysis. A representative data
set was shown in Fig. 6, the H3K9me2 level drops after treating
with CLA: 48.9% in the two-step EIA analysis (Fig. 6A); 50.85% in
WB analysis (Fig. 6B). There is no signiﬁcant difference between
the two analytical methods. Thus, the chromatin used to detect
epigenetic modiﬁcation in DNA can also be used to detect histone
modiﬁcations using the proposed method. It should be noted that
while Western Blotting analysis requires loading of separate
samples, in our method multiple epigenetic modiﬁcations can be
detected simultaneously with less sample (as much as 200 ng com-
pared to 15 lg) requiring less cells to complete the analysis [14].
Future experiments could extend the limit of multiplexing by other
highly sensitive methods such as surface enhanced Raman and
plasmon hyperspectral imaging [39,40].
4. Conclusion
Using the unique surface chemistry of modiﬁed magnetic
nanoparticles, we report a rapid one-pot chromatin extraction pro-
tocol from whole blood and to demonstrate a cross-platform
approach for simultaneous detection of epigenetic modiﬁcations
on DNA and histone proteins. With carboxyl functionalized mag-
netic nanoparticles, we have demonstrated that leucocytes can
be enriched and their chromatin can be adsorbed on to surface
modiﬁed nanoparticles in a single tube with a few simple steps.
Our sample preparation and detection strategy does not require
centrifugation, ﬁltration, fragmentation or use of hazardous agents.
Using the extracted chromatin as a substrate, we demonstrate that
epigenetic modiﬁcations on DNA and histone proteins can be
simultaneously detected via a biotin–streptavidin mediated
enzyme-based immunosorbent assay (two-step EIA), which con-
ventionally is done separately because analyzing DNA and histone
proteins involve separate steps. The developed method was
successfully validated with the conventional DNA based EIA and
Western Blotting analysis. Our approach is the ﬁrst demonstration
to propose the simultaneous detection of DNA and histone modiﬁ-
cations in the extracted chromatin. Future efforts could focus on
using the developed approach in a high throughput setting to iden-
tify changes in DNA and histone post translational modiﬁcations
which can be used as biomarkers for health screening, disease
prognosis, and for understanding normal blood cell development
and leukemogenesis.
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